Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | CXCR6 | O00574 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869565 | 1.00 | EPHX2 (0.54) | EPHX2SIGMAR1CCR2CXCR6MAPT | |
| SCHEMBL3869577 | 0.94 | EPHX2 (0.60) | EPHX2SIGMAR1CXCR6MAPTMAPK1 | |
| SCHEMBL3872069 | 0.94 | EPHX2 (0.60) | EPHX2SIGMAR1CXCR6MAPTMAPK1 | |
| SCHEMBL4671794 | 0.88 | SIGMAR1 (0.44) | EPHX2SIGMAR1CCR2CXCR6MAPT | |
| SCHEMBL4671797 | 0.88 | SIGMAR1 (0.44) | EPHX2SIGMAR1CCR2CXCR6MAPT | |
| SCHEMBL3869069 | 0.86 | CCR2 (0.69) | CCR2MEN1KMT2A | |
| SCHEMBL3870197 | 0.86 | CCR2 (0.69) | CCR2MEN1KMT2A | |
| SCHEMBL3869073 | 0.86 | CCR2 (0.69) | CCR2MEN1KMT2A | |
| SCHEMBL3871796 | 0.84 | MAPT (0.52) | EPHX2CCR2CXCR6MAPTMAPK1 | |
| SCHEMBL3871794 | 0.84 | MAPT (0.52) | EPHX2CCR2CXCR6MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | claimed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | claimed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | EPHX2 2154/4885SIGMAR1 180/4885CCR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.